Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Description

The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \< 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.

Conditions

Cardiomyopathies, Heart Failure

Study Overview

Study Details

Study overview

The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \< 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Condition
Cardiomyopathies
Intervention / Treatment

-

Contacts and Locations

Cincinnati

TriHealth Hatton Research Institute, Cincinnati, Ohio, United States, 45242

Kingwood

Texas Cardiology Associates of Houston, Kingwood, Texas, United States, 77339

McKinney

CardioVoyage, McKinney, Texas, United States, 75020

Charleston

CAMC, Charleston, West Virginia, United States, 25304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    FEMALE

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Zoll Medical Corporation,

    Valentina Kutyifa, MD PHD, PRINCIPAL_INVESTIGATOR, University of Rochester

    Study Record Dates

    2024-12